Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis.

MLA

Xinji Zhang, et al. “Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis.” PLoS ONE, vol. 7, no. 8, Aug. 2012, pp. 1–9. EBSCOhost, https://doi.org/10.1371/journal.pone.0040178.

APA

Xinji Zhang, Yesheng Li, Hui Li, Yingyi Qin, Chong Bai, Feng Xu, Tianyi Zhu, Jinfang Xu, Mengjie Wu, Chaoxiang Wang, Lixin Wei, Jia He, & Pan-Chyr Yang. (2012). Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis. PLoS ONE, 7(8), 1–9. https://doi.org/10.1371/journal.pone.0040178

Chicago

Xinji Zhang, Yesheng Li, Hui Li, Yingyi Qin, Chong Bai, Feng Xu, Tianyi Zhu, et al. 2012. “Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis.” PLoS ONE 7 (8): 1–9. doi:10.1371/journal.pone.0040178.